icon-folder.gif   Conference Reports for NATAP  
 
  18th International Workshop on
Clinical Pharmacology of Antiviral Therapy
June 14-17, 2017
Chicago, Ill.C
Back grey_arrow_rt.gif
 
 
 
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine-Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis
 
 
  Reported by Jules Levin
18th International Workshop on Clinical Pharmacology of Antiviral Therapy
Chicago, IL
 
Kimberly Adkison,1 Lesley Kahl,1 Elizabeth Blair,1 Kostas Angelis,2 Herta Crauwels,3 Maria Nascimento,1 Michael Aboud1 1ViiV Healthcare; 2GlaxoSmithKline; 3Janssen Pharmaceutica
 
CROI: SWORD 1 & 2: Switch to DTG + RPV Maintains Virologic Suppression Through 48 Weeks, a Phase III Study - (02/16/17)
 
C0, pre-dose plasma concentration; DTG, dolutegravir; EFV, efavirenz; NNRTI,
non-nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PA-IC90, protein-adjusted 90% inhibitory concentration; PK, pharmacokinetic; RPV, rilpivirine

EASL1

EASL2

EASL3

EASL4

EASL5

EASL6

EASL7

EASL8

EASL9